|
[1] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
|
|
[2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[3] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15):1450-1462.
|
|
[4] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
|
|
[5] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30.
|
|
[6] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
|
|
[7] ARZUMANYAN A,REIS HM,FEITELSON MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma[J]. Nat Rev Cancer,2013,13(2):123-135.
|
|
[8] XIAO J,WANG F,WONG NK,et al. Global liver disease burdens and research trends:Analysis from a Chinese perspective[J]. J Hepatol,2019,71(1):212-221.
|
|
[9] LEVRERO M,ZUCMAN-ROSSI J. Mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatol,2016,64(1Suppl):s84-s101.
|
|
[10] VALAYDON ZS,LOCARNINI SA. The virological aspects of hepatitis B[J]. Best Pract Res Clin Gastroenterol,2017,31(3):257-264.
|
|
[11] LIU S,KOH SS,LEE CG. Hepatitis B virus X protein and hepatocarcinogenesis[J]. Int J Mol Sci,2016,17(6):940.
|
|
[12] ZHANG B,HAN S,FENG B,et al. Hepatitis B virus X proteinmediated non-coding RNA aberrations in the development of human hepatocellular carcinoma[J]. Exp Mol Med,2017,49(2):e293.
|
|
[13] SARTORIUS K,SWADLING L,AN P,et al. The multiple roles of hepatitis B virus X protein(HBx)dysregulated microRNA in hepatitis B virus-associated hepatocellular carcinoma(HBV-HCC)and immune pathways[J]. Viruses,2020,12(7):746.
|
|
[14] XIE WH,DING J,XIE XX,et al. Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation[J]. Inflamm Res,2020,69(7):683-696.
|
|
[15] MATSUBARA K,TOKINO T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis[J]. Mol Biol Med,1990,7(3):243-260.
|
|
[16] RINGLANDER J,SKOGLUND C,PRAKASH K,et al. Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA[J]. J Viral Hepat,2020.[Online ahead of print]
|
|
[17] HUANG P,XU Q,YAN Y,et al. HBx/ERαcomplex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis[J]. Oncogene,2020,39(18):3774-3789.
|
|
[18] SALERNO D,CHIODO L,ALFANO V,et al. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription[J]. Gut,2020.[Online ahead of print]
|
|
[19] CHEN Z,YU W,ZHOU Q,et al. A novel lncRNA IHS promotes tumor proliferation and metastasis in HCC by regulating the ERK-and AKT/GSK-3β-signaling pathways[J]. Mol Ther Nucleic Acids,2019,16:707-720.
|
|
[20] YU S,LI N,HUANG Z,et al. A novel lncRNA,TCONS_00006195,represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1[J]. Cell Death Dis,2018,9(12):1184.
|
|
[21] WU G,YU F,XIAO Z,et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro[J]. Br J Cancer,2011,105(1):146-153.
|
|
[22] YANG Z,LI J,FENG G,et al. Hepatitis B virus X protein enhances hepatocarcinogenesis by depressing the targeting of NUSAP1 mRNA by miR-18b[J]. Cancer Biol Med,2019,16(2):276-287.
|
|
[23] GAO Y,GU J,WANG Y,et al. Hepatitis B virus X protein boosts hepatocellular carcinoma progression by downregulating microRNA-137[J]. Pathol Res Pract,2020,216(6):152981.
|
|
[24] HU XM,YAN XH,HU YW,et al. miRNA-548p suppresses hepatitis B virus X protein associated hepatocellular carcinoma by downregulating oncoprotein hepatitis B x-interacting protein[J]. Hepatol Res,2016,46(8):804-815.
|
|
[25] ZHANG C,LIU P,ZHANG C. Hepatitis B virus X protein upregulates alpha-fetoprotein to promote hepatocellular carcinoma by targeting miR-1236 and miR-329[J]. J Cell Biochem,2020,121(3):2489-2499.
|
|
[26] HE B,PENG F,LI W,et al. Interaction of lncRNA-MALAT1and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling[J]. J Cell Biochem,2019,120(3):2908-2918.
|
|
[27] HUANG P,XU Q,YAN Y,et al. HBx/ERαcomplex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis[J]. Oncogene,2020,39(18):3774-3789.
|
|
[28] LIU Y,FENG J,SUN M,et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma[J]. Cancer Lett,2019,454:158-170.
|
|
[29] ZHANG Q,SONG G,YAO L,et al. miR-3928v is induced by HBx via NF-κB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3[J]. J Exp Clin Cancer Res,2018,37(1):14.
|
|
[30] LIN X,ZUO S,LUO R,et al. HBX-induced miR-5188 impairs FOXO1 to stimulateβ-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma[J].Theranostics,2019,9(25):7583-7598.
|
|
[31] SONG X,TAN S,WU Z,et al. HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation[J]. Int J Cancer,2018,143(12):3120-3130.
|
|
[32] TIAN JH,LIU WD,ZHANG ZY,et al. Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2[J]. J Viral Hepat,2019,26(4):496-505.
|
|
[33] XIE X,XU X,SUN C,et al. Hepatitis B virus X protein promotes proliferation of hepatocellular carcinoma cells by upregulating miR-181b by targeting ING5[J]. Biol Chem,2018,399(6):611-619.
|
|
[34] LIU LP,LIANG HF,CHEN XP,et al. The role of NF-kappaB in hepatitis B virus X protein-mediated upregulation of VEGF and MMPs[J]. Cancer Invest,2010,28(5):443-451.
|
|
[35] HAN JM,KANG JA,HAN MH,et al. Peroxisome-localized hepatitis Bx protein increases the invasion property of hepatocellular carcinoma cells[J]. Arch Virol,2014,159(10):2549-2557.
|
|
[36] HU Z,HUANG P,YAN Y,et al. Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion[J]. Biochem Biophys Res Commun,2019,508(1):79-86.
|
|
[37] LIANG Y,ZHANG D,ZHENG T,et al. lncRNA-SOX2OT promotes hepatocellular carcinoma invasion and metastasis through miR-122-5p-mediated activation of PKM2[J].Oncogenesis,2020,9(5):54.
|
|
[38] XIE Y,DU J,LIU Z,et al. MiR-6875-3p promotes the proliferation,invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway[J]. J Exp Clin Cancer Res,2019,38(1):7.
|
|
[39] ZHAO WT,LIN XL,LIU Y,et al. miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2[J]. Lab Invest,2019,99(10):1484-1500.
|
|
[40] PETRILLO M,PATELLA F,PESAPANE F,et al. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments[J]. Future Oncol,2018,14(28):2957-2967.
|
|
[41] WEN Y,ZHOU X,LU M,et al. Bclaf1 promotes angiogenesis by regulating HIF-1αtranscription in hepatocellular carcinoma[J]. Oncogene,2019,38(11):1845-1859.
|
|
[42] MORSE MA,SUN W,KIM R,et al. The role of angiogenesis in hepatocellular carcinoma[J]. Clin Cancer Res,2019,25(3):912-920.
|
|
[43] MOON EJ,JEONG CH,JEONG JW,et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha[J]. FASEB J,2004,18(2):382-384.
|
|
[44] SANZ-CAMENO P,MARTN-VLCHEZ S,LARA-PEZZI E,et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue:Role of HBV x protein[J]. Am J Pathol,2006,169(4):1215-1222.
|
|
[45] KASTENHUBER ER,LOWE SW. Putting p53 in context[J].Cell,2017,170(6):1062-1078.
|
|
[46] CHO IR,OH M,KOH SS,et al. Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor[J]. Int J Mol Med,2012,29(4):581-586.
|
|
[47] CHENG ST,REN JH,CAI XF,et al. HBx-elevated SIRT2promotes HBV replication and hepatocarcinogenesis[J]. Biochem Biophys Res Commun,2018,496(3):904-910.
|
|
[48] CHATURVEDI VK,SINGH A,DUBEY SK,et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma[J]. Microb Pathog,2019,128:184-194.
|
|
[49] KUO TC,CHAO CC. Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression[J]. Biochem Pharmacol,2010,80(7):1093-1102.
|
|
[50] MAO K,ZHANG J,HE C,et al. Restoration of miR-193b sensitizes hepatitis B virus-associated hepatocellular carcinoma to sorafenib[J]. Cancer Lett,2014,352(2):245-252.
|
|
[51] HUANG P,ZHUANG B,ZHANG H,et al. Hepatitis B virus X protein(HBx)is responsible for resistance to targeted therapies in hepatocellular carcinoma:Ex vivo culture evidence[J]. Clin Cancer Res,2015,21(19):4420-4430.
|
|
[52] KIM KH,SHIN HJ,KIM K,et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma[J]. Gastroenterology,2007,132(5):1955-1967.
|
|
[53] NA TY,SHIN YK,ROH KJ,et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma[J]. Hepatology,2009,49(4):1122-1131.
|
|
[54] BAI PS,XIA N,SUN H,et al. Pleiotrophin,a target of miR-384,promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma[J]. J Cell Mol Med,2017,21(11):3023-3043.
|
|
[55] GHALALI A,MARTIN-RENEDO J,HGBERG J,et al. Atorvastatin decreases HBx-induced phospho-Akt in hepatocytes via P2X receptors[J]. Mol Cancer Res,2017,15(6):714-722.
|
|
[56] LIU B,FANG M,HE Z,et al. Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation[J].Cell Death Dis,2015,6:e1980.
|
|
[57] CHEN YY,WANG WH,CHE L,et al. BNIP3L-dependent mitophagy promotes HBx-induced cancer stemness of hepatocellular carcinoma cells via glycolysis metabolism reprogramming[J]. Cancers(Basel),2020,12(3):655.
|
|
[58] LIU Y,XU L,LU B,et al. LncRNA H19/microRNA-675/PPARαaxis regulates liver cell injury and energy metabolism remodelling induced by hepatitis B X protein via Akt/m TOR signalling[J]. Mol Immunol,2019,116:18-28.
|
|
[59] KUBES P,JENNE C. Immune responses in the liver[J]. Annu Rev Immunol,2018,36:247-277.
|
|
[60] PICONESE S,CAMMARATA I,BARNABA V. Viral hepatitis,inflammation,and cancer:A lesson for autoimmunity[J]. J Autoimmun,2018,95:58-68.
|
|
[61] WONG VW,YU J,CHENG AS,et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B[J]. Int J Cancer,2009,124(12):2766-2770.
|
|
[62] SHENG T,WANG B,WANG SY,et al. The relationship between serum interleukin-6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection[J]. Medicine(Baltimore),2015,94(24):e941.
|
|
[63] ZHAO L,JIN Y,YANG C,et al. HBV-specific CD8 T cells present higher TNF-αexpression but lower cytotoxicity in hepatocellular carcinoma[J]. Clin Exp Immunol,2020,201(3):289-296.
|
|
[64] LARA-PEZZI E,MAJANO PL,GMEZ-GONZALO M,et al.The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes[J]. Hepatology,1998,28(4):1013-1021.
|
|
[65] LEE MO,CHOI YH,SHIN EC,et al. Hepatitis B virus X protein induced expression of interleukin 18(IL-18):A potential mechanism for liver injury caused by hepatitis B virus(HBV)infection[J]. J Hepatol,2002,37(3):380-386.
|
|
[66] AMIRPOUR-ROSTAMI S,KAZEMI ARABABADI M. IL-18 and IL-1βgene polymorphisms:The plausible risk factors for chronic hepatitis B[J]. Viral Immunol,2019,32(5):208-213.
|
|
[67] YU X,LAN P,HOU X,et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1βproduction via suppressing the NF-κB pathway and ROS production[J]. J Hepatol,2017,66(4):693-702.
|
|
[68] SUNAMI Y,RINGELHAN M,KOKAI E,et al. Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response[J]. Hepatology,2016,63(5):1592-1607.
|
|
[69] SCHINZARI V,TIMPERI E,PECORA G,et al. Wnt3a/β-catenin signaling conditions differentiation of partially exhausted T-effector cells in human cancers[J]. Cancer Immunol Res,2018,6(8):941-952.
|
|
[70] SHI H,HE H,OJHA SC,et al. Association of STAT3 and STAT4 polymorphisms with susceptibility to chronic hepatitis B virus infection and risk of hepatocellular carcinoma:A metaanalysis[J]. Biosci Rep,2019,39(6):BSR20190783.
|
|
[71] YU LX,LING Y,WANG HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression[J].NPJ Precis Oncol,2018,2(1):6.
|
|
[72] SEKIBA K,OTSUKA M,OHNO M,et al. Hepatitis B virus pathogenesis:Fresh insights into hepatitis B virus RNA[J].World J Gastroenterol,2018,24(21):2261-2268.
|
|
[73] LI X,ZHANG J,YANG Z,et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma[J]. J Hepatol,2014,60(5):975-984.
|
|
[74] ZHAO LH,LIU X,YAN HX,et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma[J].Nat Commun,2016,7:12992.
|
|
[75] WONG DK,CHENG S,MAK LL,et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma,a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis[J]. Clin Gastroenterol Hepatol,2020,18(2):449-456.
|
DownLoad: